Excelsior Biopharma Inc. (TPEX:6496)
Taiwan · Delayed Price · Currency is TWD 24.35
+0.10 (0.41%)
Jul 30, 2026, 1:22 PM CST
Excelsior Biopharma Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 906.42 | 898.26 | 861.91 | 771.56 | 671.76 | 1,338 |
Revenue Growth | 2.80% | 4.22% | 11.71% | 14.86% | -49.81% | -7.29% |
Gross Profit Gross Profit Growth | 356.05 | 360.17 | 382.1 | 306.93 | 287.17 | 293.35 |
Operating Income Operating Income Growth | -187.52 | -171.6 | -80.97 | -81.13 | -29.29 | -8.77 |
Net Income Net Income Growth | -197.05 | -183.17 | -98.71 | -91.01 | -33.76 | -15.65 |
Earnings Per Share EPS Growth | -4.26 | -3.97 | -2.14 | -1.98 | -0.74 | -0.34 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Taiwan Taiwan Growth | 857.44 | 861.23 | 797.79 | 722.07 | 637.96 | 1,297 |
China China Growth | 48.45 | 35.99 | 56.6 | 48.4 | 33.62 | 40.96 |
Others Others Growth | 0.53 | 1.05 | 7.53 | 1.08 | 0.18 | 0.83 |
Total Total Growth | 906.42 | 898.26 | 861.91 | 771.56 | 671.76 | 1,338 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 130.61 | 185.34 | 251.53 | 589.92 | 1,106 | 1,103 |
Total Debt Total Debt Growth | 498.72 | 511.31 | 410.59 | 354.22 | 351.24 | 364.63 |
Net Cash (Debt) Net Cash Growth | -368.11 | -325.98 | -159.07 | 235.7 | 755.23 | 738.13 |
Net Cash Growth | - | - | - | -68.79% | 2.32% | -5.08% |
Net Cash Per Share Net Cash Per Share Growth | -7.96 | -7.06 | -3.45 | 5.13 | 16.47 | 15.87 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -123.95 | -138.72 | -99.8 | -134.75 | 5.49 | 55.82 |
Capital Expenditures CapEx Growth | -25.33 | -36.95 | -257.15 | -35.66 | -7.78 | -2.88 |
Free Cash Flow Free Cash Flow Growth | -149.28 | -175.67 | -356.95 | -170.41 | -2.3 | 52.95 |
Free Cash Flow Growth | - | - | - | - | - | -89.60% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 39.28% | 40.10% | 44.33% | 39.78% | 42.75% | 21.92% |
Operating Margin | -20.69% | -19.10% | -9.40% | -10.51% | -4.36% | -0.66% |
Pretax Margin | -20.63% | -19.19% | -10.14% | -10.62% | -3.87% | -0.75% |
Profit Margin | -21.74% | -20.39% | -11.45% | -11.80% | -5.03% | -1.17% |
FCF Margin | -16.47% | -19.56% | -41.41% | -22.09% | -0.34% | 3.96% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 10.56 | 10.56 | 10.56 | 10.56 | 10.56 |
P/FCF Ratio | - | - | - | - | - | 25.75 |
PS Ratio | 1.25 | 1.52 | 1.63 | 1.76 | 1.93 | 1.02 |